Competitive Technologies Licensee Moves to Phase I/II Testing of Anti-Angiogenic Ribozyme Technology.
Business Wire › November 18, 1999
Linked as:
Extract
Competitive Technologies Licensee Moves to Phase I/II Testing of Anti-Angiogenic Ribozyme Technology.
FAIRFIELD, Conn.--(BUSINESS WIRE)--Nov. 18, 1999--
Initial studies of Anti-Hepatitis C Virus Ribozyme Demonstrate Potent Anti-viral Activity IND Planned for Filing by End of 1999 ...See the full content of this document
Sponsored links
